Pentoxifylline

Mucositis

Tanta UniversitySmall moleculeEarly Phase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the Mucositis cohort.

Asset / Sponsor	Phase	Rating
Fentanyl Sublingual Spray INSYS Therapeutics Inc	Phase 3	BB
Palifermin Barbara Ann Karmanos Cancer Institute	Phase 3	BB
CALCIUM PHOSPHATE Children's Oncology Group	Phase 3	BB
Everolimus Emory University	Phase 2	CCC
Folic Acid Niels Fristrup	Phase 2	CCC

View all 9 →

Same molecule, other indications

Pentoxifylline is also rated in:

metabolic dysfunction-associated steatohepatitisDormant

BBB

Indicative ·

76 / 100

Neuralgia PeripheralDormant

BB

Indicative ·

69 / 100

type 2 diabetes mellitusDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.